Clinical value of FDG-PET for therapy monitoring of malignant lymphoma - Results of a retrospective study in 72 patients;Klinische wertigkeit der FDG-PET zur therapie-kontrolle bei malignen lymphomen - Ergebnisse einer retrospektiven studie an 72 patienten

NuklearMedizin

Volumn 38, Issue 1, 1999, Pages 24-30

  Cremerius, U ^a   Fabry, U ^b   Kroll U ^b   Zimny, M ^b   Neuerburg, J ^b   Osieka, R ^b   Bull U ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE

Author keywords

Bayes' theorem; Fluorine 18 fluorodeoxyglucose; Lactate dehydrogenase; Malignant lymphoma; Positron emission tomography; Therapy monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 0032907078     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632184     Document Type: Article

References (24)

1. Bares R, Klever P, Hauptmann S et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86.
2. Bumann D, de Wit M, Beyer W et al. Computertomographie und F-18-FDG-Positronen-Emissions-Tomographie im Staging maligner Lymphome: ein Vergleich. Fortschr Röntgenstr 1998; 168: 457-65.
3. Cabanillas F, Velasquez WS, Hagemeister FB et al. Clinical, biologic and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992; 79: 1024-8.
4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-3.
5. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with fluorine-18 fluorodeoxyglucose to detect residual disease after therapy of malignant lymphoma. Nucl Med Commun (im Druck).
6. De Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8: Suppl 1:57-60.
7. Detrano R, Yiannikas J, Salcedo EE et al. Bayesian probability analysis: a prospective demonstration of its clinical utility in diagnosing coronary artery disease. Circulation 1984; 69: 541-5.
8. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-42.
9. Engel H, Steinert H, Buck A, Berthold T, Huch-Böni R, von Schulthess GK. Whole-body PET: phyiological and artifactual fluorodeoxyglucose accumulation. J Nucl Med 1996; 37: 441-6.
10. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-10.
11. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-8.
12. Kennedy BJ, Loeb V, Peterson V et al. Survival in Hodgkin's disease by stage and age. Medical and Pediatric Oncology 1992; 20: 100-4.
13. Lapela M, Leskinen S, Minn H et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-7.
14. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
15. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-6.
16. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-91.
17. Radford JA, Cowan RA, Flanagan M et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940-6.
18. Reske SN. Positronen-Emissions-Tomographie in der Onkologie. Deutsches Ärzteblatt 1998;95:81495-7.
19. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-15.
20. Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthcss GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
21. Surbone A, Longo DL, De Vita VT et al. Residual abdominal masses in aggressive non-Hodgkin lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832-7.
22. The International Non-Hodgkin's Lymphoma Prognostic factors Project. A predictive model for aggressive non-Hodgkin-lymphoma. New Engl J Med 1993; 329: 987-94.
23. Thill R, Neuerburg J, Fabry U et al. Vergleich der Befunde von 18-FDG-PET und CT beim prätherapeutischen Staging maligner Lymphome. Nuklearmedizin 1997; 36: 234-9.
24. Vose JM, Anderson JR, Kessinger A, Biermann PJ et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin-lymphoma. J Clin Oncol 1993; 11: 1846-51.